دورية أكاديمية
أعرض في EDS

Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis.

التفاصيل البيبلوغرافية
العنوان: Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis.
المؤلفون: Lage DP; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 30130-100, Brazil., Ribeiro PAF; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 30130-100, Brazil., Dias DS; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 30130-100, Brazil., Mendonça DVC; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 30130-100, Brazil., Ramos FF; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 30130-100, Brazil., Carvalho LM; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas/NUPEB, Departamento de Ciências Biológicas, Insituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais 35400-000, Brazil., Steiner BT; Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 31270-901, Brazil., Tavares GSV; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 30130-100, Brazil., Martins VT; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 30130-100, Brazil., Machado AS; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 30130-100, Brazil., Oliveira-da-Silva JA; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 30130-100, Brazil., Santos TTO; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 30130-100, Brazil., Freitas CS; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 30130-100, Brazil., Oliveira JS; Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, Criciúma, Santa Catarina 88806-000, Brazil., Roatt BM; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas/NUPEB, Departamento de Ciências Biológicas, Insituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais 35400-000, Brazil., Machado-de-Ávila RA; Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 31270-901, Brazil., Humbert MV; Neisseria Research Group, Molecular Microbiology, School of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton SO16 6YD, UK., Christodoulides M; Neisseria Research Group, Molecular Microbiology, School of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton SO16 6YD, UK., Coelho EAF; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 30130-100, Brazil.
المصدر: Vaccines [Vaccines (Basel)] 2020 Jun 09; Vol. 8 (2). Date of Electronic Publication: 2020 Jun 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG
مستخلص: Background : Leishmaniases are neglected diseases caused by infection with Leishmania parasites and there are no human vaccines in use routinely. The purpose of this study was to examine the immunogenicity of ChimeraT, a novel synthetic recombinant vaccine against visceral leishmaniasis (VL), incorporated into a human-compatible liposome formulation. Methods : BALB/c mice were immunized subcutaneously with ChimeraT/liposome vaccine, ChimeraT/saponin adjuvant, or ChimeraT/saline and immune responses examined in vitro and in vivo. Results : Immunization with the ChimeraT/liposome formulation induced a polarized Th1-type response and significant protection against L. infantum infection. ChimeraT/liposome vaccine stimulated significantly high levels of interferon (IFN)-γ, interleukin (IL)-12, and granulocyte macrophage-colony stimulating factor (GM-CSF) cytokines by both CD4 and CD8 T-cells, with correspondingly lower levels of IL-4 and IL-10 cytokines. Induced antibodies were predominantly IgG2a isotype, and homologous antigen-stimulated spleen cells produced significant nitrite as a proxy for nitric oxide (NO). Furthermore, we examined a small number of treated VL patients and found higher levels of circulating anti-ChimeraT protein IgG2 antibodies, compared to IgG1 levels. Conclusions : Overall, the liposomal formulation of ChimeraT induced a protective Th1-type immune response and thus could be considered in future studies as a vaccine candidate against human VL.
References: Clin Vaccine Immunol. 2015 Nov;22(11):1187-96. (PMID: 26376929)
Clin Microbiol Rev. 1993 Jul;6(3):230-50. (PMID: 8358705)
J Antimicrob Chemother. 2018 Feb 1;73(2):392-394. (PMID: 29165590)
mSphere. 2019 May 1;4(3):. (PMID: 31043512)
Cell Immunol. 2018 Jan;323:59-69. (PMID: 29128045)
Parasitology. 2018 Apr;145(4):464-480. (PMID: 28103966)
Exp Parasitol. 2012 Dec;132(4):403-9. (PMID: 22982807)
Clin Diagn Lab Immunol. 1995 May;2(3):291-6. (PMID: 7664174)
Asian Pac J Trop Med. 2015 Jul;8(7):513-9. (PMID: 26276280)
Mol Immunol. 2019 Feb;106:108-118. (PMID: 30594673)
Infect Immun. 2003 Jul;71(7):3988-94. (PMID: 12819086)
J Infect Dis. 2018 Oct 5;218(10):1541-1550. (PMID: 29893872)
Vaccine. 2019 Jun 12;37(27):3505-3519. (PMID: 31103364)
J Clin Lab Anal. 2000;14(1):5-12. (PMID: 10645978)
Diagn Microbiol Infect Dis. 2019 Oct;95(2):134-143. (PMID: 31155395)
Infect Immun. 2018 Apr 23;86(5):. (PMID: 29483288)
PLoS Negl Trop Dis. 2017 Jan 23;11(1):e0005311. (PMID: 28114333)
Expert Opin Drug Deliv. 2011 Apr;8(4):505-19. (PMID: 21413904)
Parasite Immunol. 2015 Apr;37(4):192-203. (PMID: 25615543)
Parasite Immunol. 2016 Nov;38(11):670-677. (PMID: 27540714)
Front Immunol. 2019 Feb 28;10:288. (PMID: 30873164)
Am J Trop Med Hyg. 2015 Dec;93(6):1214-8. (PMID: 26483120)
Cytokine. 2020 Feb 12;129:155031. (PMID: 32062145)
Drug Discov Today. 2009 Jun;14(11-12):541-51. (PMID: 19508916)
EBioMedicine. 2018 Oct;36:83-91. (PMID: 30268832)
Clin Infect Dis. 2013 Jun;56(11):1530-8. (PMID: 23425958)
Immunol Today. 2000 Feb;21(2):73-8. (PMID: 10652464)
Methods Mol Biol. 2007;409:185-200. (PMID: 18450001)
Ther Adv Infect Dis. 2016 Jun;3(3-4):98-109. (PMID: 27536354)
Vaccine. 2018 Apr 19;36(17):2293-2299. (PMID: 29573875)
Anal Biochem. 1982 Oct;126(1):131-8. (PMID: 7181105)
Transl Res. 2018 Oct;200:18-34. (PMID: 29908151)
Acta Trop. 2017 Jul;171:8-16. (PMID: 28288798)
PLoS Negl Trop Dis. 2019 Feb 11;13(2):e0007173. (PMID: 30742620)
PLoS Negl Trop Dis. 2019 Mar 27;13(3):e0007216. (PMID: 30917114)
Parasitol Int. 2016 Dec;65(6 Pt A):728-736. (PMID: 27425599)
Nucleic Acids Res. 2003 Jul 1;31(13):3784-8. (PMID: 12824418)
Infect Immun. 1998 Jan;66(1):18-27. (PMID: 9423834)
Parasite Immunol. 2017 Jan;39(1):. (PMID: 27593711)
J Zhejiang Univ Sci B. 2007 Mar;8(3):153-61. (PMID: 17323426)
Acta Trop. 2016 Feb;154:73-81. (PMID: 26593442)
J Immunol Res. 2019 Apr 30;2019:9124326. (PMID: 31183394)
Ther Adv Vaccines. 2017 Aug;5(4-5):85-101. (PMID: 29201374)
J Clin Microbiol. 2002 Mar;40(3):1037-43. (PMID: 11880434)
Parasitology. 2019 Sep;146(11):1467-1476. (PMID: 31142384)
Hum Immunol. 2009 Jun;70(6):383-90. (PMID: 19480861)
Microbes Infect. 2018 Jan;20(1):37-47. (PMID: 28970116)
Antimicrob Agents Chemother. 2019 Jun 24;63(7):. (PMID: 31036692)
Front Immunol. 2017 Feb 23;8:100. (PMID: 28280494)
Mol Immunol. 2018 Nov;103:7-20. (PMID: 30173073)
Mol Immunol. 2016 Aug;76:70-9. (PMID: 27387277)
J Biomed Mater Res B Appl Biomater. 2018 May;106(4):1587-1594. (PMID: 28804955)
Front Immunol. 2019 Apr 05;10:670. (PMID: 31024534)
Int Immunopharmacol. 2018 Jun;59:97-105. (PMID: 29649772)
Immunobiology. 2018 Mar;223(3):303-309. (PMID: 29074301)
Cell Microbiol. 2010 Apr 1;12(4):432-52. (PMID: 19888987)
Scand J Immunol. 2017 Jul;86(1):15-22. (PMID: 28426153)
Parasitology. 2018 Apr;145(4):481-489. (PMID: 29215329)
PLoS Negl Trop Dis. 2012;6(10):e1874. (PMID: 23150744)
Vaccine. 2013 Jan 21;31(5):735-49. (PMID: 23219436)
Parasite Immunol. 2006 May;28(5):173-83. (PMID: 16629702)
Clin Diagn Lab Immunol. 1999 Mar;6(2):231-5. (PMID: 10066659)
Int J Nanomedicine. 2019 May 02;14:3203-3220. (PMID: 31118632)
Immunobiology. 2015 Sep;220(9):1031-8. (PMID: 26001730)
Parasit Vectors. 2015 Jul 11;8:363. (PMID: 26160291)
Mater Sci Eng C Mater Biol Appl. 2017 Dec 1;81:327-333. (PMID: 28887980)
Front Immunol. 2018 Nov 16;9:2558. (PMID: 30519235)
Parasitology. 2014 Jul 30;:1-19. (PMID: 25075460)
Rev Soc Bras Med Trop. 2016 Jul-Aug;49(4):398-407. (PMID: 27598624)
Parasitology. 2018 May;145(6):740-751. (PMID: 29113597)
Int J Mol Sci. 2019 Apr 12;20(8):. (PMID: 31013713)
Vaccines (Basel). 2019 Oct 28;7(4):. (PMID: 31661776)
Cytokine. 2018 Nov;111:131-139. (PMID: 30142534)
Cell Immunol. 2017 Mar;313:32-42. (PMID: 28049560)
BMC Infect Dis. 2005 Dec 19;5:113. (PMID: 16364177)
Mol Biochem Parasitol. 2012 Jun;183(2):140-50. (PMID: 22387760)
Front Immunol. 2018 Jan 30;9:18. (PMID: 29441060)
PLoS Negl Trop Dis. 2013 Apr 18;7(4):e2174. (PMID: 23638195)
Trends Parasitol. 2015 Dec;31(12):653-664. (PMID: 26440786)
معلومات مُعتمدة: MR/R005850/1 United Kingdom MRC_ Medical Research Council; APQ-408675/2018-7 Conselho Nacional de Desenvolvimento Científico e Tecnológico
فهرسة مساهمة: Keywords: ChimeraT; Th1-type immunity; liposome; saponin; vaccine; visceral leishmaniasis
تواريخ الأحداث: Date Created: 20200613 Latest Revision: 20220319
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7349940
DOI: 10.3390/vaccines8020289
PMID: 32526867
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-393X
DOI:10.3390/vaccines8020289